HEALTHCARE · PHARMACEUTICAL LAUNCH
A European pharmaceutical company was preparing the launch of a new hypertension treatment : differentiated mechanism of action, single daily dose, improved tolerability profile. A €4,2 billion annual European market, with 32 million patients treated.
For the pharmaceutical company, it is a new treatment. For the patient, it enters a routine that already includes daily medication.
THE CONTEXT
The treatment had a differentiated mechanism of action enabling a single daily dose and an improved tolerability profile compared with standard treatments. The commercial potential was significant : €4,2 billion annually in the European antihypertensive market, with 32 million patients treated.
The risk identified by marketing was not a lack of medical need, but the negative perception of an additional treatment among chronic hypertension patients. Qualitative studies showed medication fatigue and growing resistance to adding a new treatment, perceived as an acknowledgment that previous treatments had failed.
Marketing used our system to test 5 positioning territories — scientific innovation, improved tolerability, simplified dosing, therapeutic alternative, medication-pathway simplification — across the 22 medication-attitude profiles identified in the population.
WHAT IS ESTABLISHED
WHAT DIFFERS FOR EACH GROUP
THE FIRST RESULT
71 % of patients trust their physician regarding the effectiveness of their current treatment. The problem is therefore not belief in the medication, but fatigue with the medication burden.
A MECHANISM : WHAT AN ADDITION MEANS
Knowing the product attributes is not enough. You need to understand what they mean in the patient's life, where the treatment enters an already established routine.
The same feature can carry an opposite meaning depending on the population receiving it : progress on one side, additional burden on the other.
TWO READINGS OF THE SAME TREATMENT
The simulation does not merely compare messages. It makes visible the meaning the product takes on in the real situation of the people for whom it is intended.
WHAT IS TESTED
The five territories do not differ in molecule, dosage or tolerability profile. They differ in what the treatment does within the patient's pathway : adding something, or taking something away.
3 200 synthetic patients were interviewed about the 5 positioning territories, with dynamic follow-up questions on friction points. In parallel, 480 synthetic prescribers — general practitioners and cardiologists — were exposed to the same territories to assess consistency between patient and prescriber perceptions. Adoption trajectories were projected over 18 months, modeling prescriber-patient dynamics.
The reconstructed population covers 1,8 million European hypertension patients treated for more than 3 years, calibrated on public data — Direction de la recherche, des études, de l'évaluation et des statistiques, European surveys of hypertension patients — and on the pharmaceutical company's proprietary data.
It is structured into 22 medication-attitude profiles combining length of treatment, medication burden, trust in the treating physician and relationship to chronic medication.
LENGTH OF TREATMENT
being treated for three years or fifteen years does not produce the same relationship to a new treatment
MEDICATION BURDEN
the number of daily doses already in place changes what an additional dose means
TRUST IN THE TREATING PHYSICIAN
trust in the prescriber shapes how what they propose is received
RELATIONSHIP TO CHRONIC MEDICATION
experiencing treatment as an integrated routine or as an imposed constraint does not amount to the same experience
ADHERENCE OVER TIME
adherence is not a stable state: it deteriorates or is maintained depending on the trajectory
MEANING ATTACHED TO AN ADDITION
one more treatment can be read as progress or as a sign of worsening disease
These configurations reveal part of the population's heterogeneity. The simulation operates on synthetic individuals, not a handful of persona types.
REACTIONS
THE REJECTION IS NOT ABOUT EFFECTIVENESS
71 % of patients trust their physician regarding the effectiveness of their current treatment. What is rejected is not the medication but the prospect of adding one more to an already heavy regimen. This fatigue is structural among patients treated for more than 3 years and results in lower adherence rates at 24 months.
THE FRAMING CHANGES THE STATUS OF THE SAME TREATMENT
The scientific innovation positioning achieves 34 % patient support and 62 % prescriber support. The medication-pathway simplification positioning — presenting the treatment as a substitute that can reduce the total number of daily medications — achieves 71 % patient support and 68 % prescriber support. The product is identical; its meaning is not.
THE ORDER OF AUDIENCES CHANGES THE TRAJECTORY
General-public communication before launch reduces the program's credibility among prescribers by 24 points. Communication addressed first to prescribers using the simplification narrative, followed 6 months later by patient communication centered on quality of life, achieves an adoption trajectory 42 % higher than the reverse strategy.
34 % and 62 % support for the scientific innovation positioning, 71 % and 68 % for the medication-pathway simplification positioning. It is the same treatment, the same dosage, the same population.
REVERSING THE FRAMING
Management thought it had to answer one question : how to demonstrate the value of the innovation. The simulation reveals another : how to reduce the perceived burden of treatment.
The system does not merely choose between five messages. It makes visible the problem the patient is actually trying to solve.
TWO SEQUENCES
General-public communication before launch reduces the program's credibility among prescribers by 24 points. The reverse sequence — prescribers informed, adoption of the simplification framing, then patient communication six months later on quality of life and simplification — achieves an adoption trajectory 42 % higher.
These two trajectories involve the same product and the same message. Only the order in which the two populations are exposed differs.
A MECHANISM : LEGITIMACY
If the patient receives the launch narrative before the prescriber has adopted the positioning, the relationship into which the treatment must enter is changed. Marketing can erode legitimacy when it precedes the system of trust that supports it.
A MECHANISM : ADHERENCE
Initial prescription and adherence are not the same thing. Adoption trajectories were projected over 18 months, modeling prescriber-patient dynamics.
Patients and prescribers are not two separate panels : they form a system in which each side's reaction changes the other's.
COMPARISON
Only the territories for which the case documents measurements carry numerical values. The other three territories were tested, but no quantified result is published here : “ not published ” is retained rather than an estimate.
THE MOST ACCEPTED
Medication-pathway simplification prescribers informed first patient communication six months later
THE MOST FRAGILE
Scientific innovation alone general-public communication before launch
THE PARADOX
The innovation is real : differentiated mechanism, single daily dose, improved tolerability. What the simulation shows is that these qualities are not received in the abstract, but within a day that already contains several doses.
The real problem could therefore be cumulative burden, not the performance of the new product. An innovation can be better received when it is presented as simplification.
DECISION
PROJECTION, THEN OBSERVATION
The pharmaceutical company selected the positioning centered on medication-pathway simplification, with communication to prescribers during the first 6 months, followed by patient communication centered on quality of life and simplification, accompanied by a connected adherence-monitoring program.
At 18 months, prescriber adoption reaches 42 %, above the 34 % projection for the scientific innovation scenario. Patient adherence measured at 12 months is 78 %, versus a 62 % category average for antihypertensives. The “ one more pill ” perception measured in the patient survey is 24 %, versus 71 % in the scientific innovation positioning scenario.
These values describe what was observed after the decision. They concern perception, adoption and adherence, and do not establish exclusive causality between the selected positioning and any of these changes.
TAKEAWAY
In saturated therapeutic categories — hypertension, cholesterol, diabetes, chronic pain — conventional scientific-innovation positioning encounters structural fatigue. An inverted positioning, presenting the treatment as a tool for simplification rather than addition, changes how it is received.
The second lesson concerns order. Prior general-public communication, even if effective in building awareness, erodes prescriber credibility and compromises adoption. The prescriber-then-patient sequence preserves the treatment's medical legitimacy and improves the overall adoption trajectory.
POSSIBLE FUTURES
A
INNOVATE
The differentiated mechanism of action is placed at the center of the launch narrative
B
SIMPLIFY
The treatment is presented as a simplification of the medication pathway
C
SIMPLIFY, THEN SEQUENCE
Prescribers informed first, patient communication six months later
METHOD
1,8 million European hypertension patients treated for more than 3 years, 22 medication-attitude profiles, 5 positioning territories, 3 200 synthetic patients interviewed with dynamic follow-up on friction points, 480 synthetic prescribers — general practitioners and cardiologists — exposed to the same territories, and an 18-month projection of adoption trajectories modeling prescriber-patient dynamics.
This case adds three mechanisms to the library : the real problem may be cumulative burden rather than new-product performance ; an innovation may be better received when presented as simplification ; and the order in which several interdependent populations are exposed changes the adoption trajectory.
This case is based on a simulation carried out for a European pharmaceutical company. The commissioning client is not named, the treatment cannot be identified, no personally identifiable data entered the system, and the detailed results remain the property of the commissioning client.
The simulation concerns perception, adoption, the patient-prescriber relationship and behavioral trajectories. It is neither a clinical demonstration of effectiveness, nor a therapeutic recommendation, nor a medical decision, nor individual advice.
Your next decision
Describe your need. We can point you to the right level of support.
State your decision. See the future it produces.
